Ocular Therapeutix (Nasdaq:OCUL) announced today that it made two additions to its executive leadership team. Bedford, Massachusetts-based Ocular Therapeutix appointed a chief medical advisor (CMA) — a newly created role — as well as a new chief medical officer (CMO). Additionally, the company created a new role called chief strategy advisor (CSA) for its departing […]
Ocular Therapeutix
Ocular Therapeutix posts mixed-bag Q1 results
Ocular Therapeutix (NSDQ:OCUL) this week posted first-quarter results that beat the earnings consensus on Wall Street but missed revenue estimates. The Bedford, Massachusetts-based company reported losses of $12.5 million, or -16¢ per share, on sales of $13.2 million for the three months ended March 31, for sales growth of 79.6% compared with Q1 2021. Earnings […]
Ocular Therapeutix misses on Q4 projections
Ocular Therapeutix (NSDQ:OCUL) shares ticked up today despite fourth-quarter results that missed the consensus revenue forecast. The Bedford, Massachusetts-based company posted losses of $3.9 million, or 5¢ per share, on sales of $12.3 million for the three months ended Dec. 31, 2021, for a massive bottom-line gain moving from $85.6 million in losses this time […]
Ocular Therapeutix touts positive trial results of ophthalmic insert for dry eye disease
Ocular Therapeutix (NSDQ:OCUL) announced today that it reported positive results from a Phase 2 trial of its dry eye disease treatment. Bedford, Massachusetts-based Ocular Therapeutix’s U.S.-based Phase 2 clinical trial evaluated OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease. Get the full story at our sister site, Drug Delivery Business News.
Ocular Therapeutix claims win as court invalidates drug delivery patent from Mati
Ocular Therapeutix (NSDQ:OCUL) announced today that an appeals court invalidated a drug delivery system patent held by Mati Therapeutics. The U.S. Court of Appeals for the Federal Circuit in Washington, D.C., invalidated the patent related to a drug delivery system containing dexamethasone, affirming the judgment made in June 2020 by the Patent Trial and Appeal Board […]
Ocular Therapeutix dry eye treatment trial fails to meet primary endpoint
Ocular Therapeutix (NSDQ:OCUL) announced today that its Phase 2 clinical trial for treating dry eye disease (DED) did not meet its primary endpoint. Bedford, Massachusetts-based Ocular Therapeutix’s U.S.-based, randomized, double-masked, multi-center, vehicle-controlled Phase 2 clinical trial evaluated OTX-CSI (cyclosporine intracanalicular insert) for treating DED by measuring signs and symptoms of DED in 140 subjects treated in […]
Ocular Therapeutix misses on earnings, tops Q2 revenue estimates
Ocular Therapeutix (NSDQ:OCUL) shares ticked up this morning on second-quarter results that topped revenue forecasts. OCUL shares were up nearly 2% at $10.94 apiece in morning trading today. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was down slightly. Get the full story at our sister site, Drug Delivery Business […]
Ocular Therapeutix misses The Street on bottom-line leap
Ocular Therapeutix (NSDQ:OCUL) reported first-quarter results that missed the consensus forecast on Wall Street. The Bedford, Mass.–based eye disease therapeutic developer posted profits of $3.12 million, or $0.04 per share, on sales of $7.34 million for the three months ended March 31, 2021, for a bottom-line leap of 114% on sales growth of 181% compared […]
Ocular Therapeutix reports Q4 misses
Ocular Therapeutix (NSDQ:OCUL) reported fourth-quarter results that missed the consensus forecast. The Bedford, Mass.–based eye disease therapeutic developer posted losses of –$85.6 million, or –$1.21 per share, on sales of $7.3 million for the three months ended Dec. 31, 2020, for a massive bottom-line slide from losses of –$26 million last year despite more than […]
Ocular Therapeutix commences public offering
Ocular Therapeutix (NSDQ:OCUL) announced that it commenced an underwritten public offering of an undisclosed amount of its common stock. The Bedford, Mass.-based eye condition therapy developer filed with the SEC to confirm the offering with the shares at a par value of $0.0001 per share. The common stock at market close on May 18 prior to […]
Ocular Therapeutix posts wider-than-forecast Q1 results
Ocular Therapeutix (NSDQ:OCUL) posted first-quarter results that beat the revenue consensus on Wall Street but missed on earnings. The company reported losses of -$21.5 million, or -41¢ per share, on sales of $2.6 million for the three months ended March 31, for a sales growth of 430.3% compared with Q1 2019. Earnings per share were -41¢, […]
